- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03944915
De-Escalation Therapy for Human Papillomavirus Negative Disease (DEPEND)
A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Everett Vokes, MD
- Phone Number: 773-702-9306
- Email: evokes@medicine.bsd.uchicago.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago Medicine Comprehensive Cancer Center
-
Contact:
- Everett Vokes, MD
- Phone Number: 773-702-9306
- Email: evokes@medicine.bsd.uchicago.edu
-
Principal Investigator:
- Everett Vokes, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have pathologically confirmed locally advanced, non-metastatic, HPV-negative head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, nasopharynx, larynx, or sinuses.
- Stage IV disease with the exception of nasopharyngeal tumor-3, node-2 (stage III) based of American Joint Committee on Cancer staging 8th edition
- If a primary oropharyngeal squamous cell carcinoma is diagnosed, HPV must be ruled out by immunohistochemistry.
- Availability of ≥10 unstained 5 micron slides. Patients who cannot fulfill this requirement will need to undergo a new biopsy prior to enrollment on study.
- Patients must be at least 18 years of age.
- Measurable disease (either primary site and/or nodal disease) by RECIST criteria.
- No previous radiation or chemotherapy for a head and neck cancer.
- No complete surgical resection for a head and neck cancer within 8 weeks of enrollment (although lymph node biopsy including excision of an individual node with presence of residual nodal disease, or surgical biopsy/excision of the tumor with residual measurable disease is acceptable.) No surgical procedures or biopsies will occur after baseline scans are performed and measurable lesions are identified.
- Eastern Cooperative Oncology Group performance status 0-1
Normal Organ Function
- Leukocytes ≥ 3000/mm3
- Platelets ≥ 100,000/mm3
- Absolute neutrophil count ≥ 1,500
- Hemoglobin ≥ 9.0 gm/dL
- Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5x upper limit of normal
- Alkaline phosphatase ≤ 2.5x upper limit of normal
- Albumin > 2.9 gm/dL
- Total bilirubin ≤ 1.5 mg/dL
- Creatinine clearance > 45 mL/min, normal within 2 weeks prior to start of treatment (Of note, the standard Cockcroft and Gault formula must be used to calculate creatinine clearance (CrCl) for enrollment or dosing)
- Patients must sign a study-specific informed consent form prior to study entry. Patients should have the ability to understand and the willingness to sign a written informed consent document.
- Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug
- Women must not be breastfeeding
- Women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 6 months after completing chemoradiation or receiving the last dose of consolidative nivolumab, whichever occurs latest.
- Men who are sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 6 months after completing chemoradiation or receiving the last dose of consolidative nivolumab, whichever occurs latest.
Exclusion Criteria:
- Unequivocal demonstration of distant metastatic disease (M1 disease).
- Unidentifiable primary site.
- Inter-current medical illnesses which would impair patient tolerance to therapy or limit survival. This includes but is not limited to ongoing or active infection, immunodeficiency, symptomatic congestive heart failure, pulmonary dysfunction, cardiomyopathy, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance. Patients with clinically stable and/or chronically managed medical illnesses that are not symptomatic and/or are not expected to impact treatment on protocol are still eligible (conditions to be reviewed by the PI to confirm eligibility)
- Prior surgical therapy other than incisional/excisional biopsy or organ-sparing procedures such as debulking of airway-compromising tumors. Residual measurable tumor is required for enrollment as discussed above.
- Patients receiving other investigational agents.
- Diagnosis of immunodeficiency or is receiving systemic steroid therapy in excess of physiologic dose or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Known history of active tuberculosis (Bacillus Tuberculosis infection).
- Hypersensitivity to nivolumab or any other drug used in this protocol.
- Prior systemic anti-cancer treatment within the last 8 weeks.
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer or any tumors that are not likely to influence life expectancy in the subsequent 3 years without active treatment.
- Has active autoimmune disease that has required systemic therapy in the past year (i.e. with steroids or immunosuppressive drugs). Replacement therapy e.g. levothyroxine, insulin, or physiologic corticosteroid doses for adrenal or pituitary insufficiency, etc. are not considered a form of systemic treatment.
- Has known history of, or any evidence of active, non-infectious pneumonitis.
- Has a history of HIV.
- Has known active Hepatitis B or hepatitis C. If eradicated, patient is eligible.
- Has received a live vaccine within 28 days of planned start of study therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARM 1
Induction Therapy
|
Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle.
Each cycle will last 21 days.
There will be 3 cycles.
During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles. During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy.
Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.
|
Experimental: ARM 2
Radiation therapy with chemotherapy
|
During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles. During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy.
Patients will receive 4.5-5 cycles of radiation depending on response.
Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy.
Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13
One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle
5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles
Other Names:
Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.
Other Names:
Radiotherapy may also be given with a different chemotherapy agent called cisplatin.
This is the traditional standard of care chemotherapy regimen.
In this case, the radiotherapy will be given once daily for 5 days per week.
Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Deep Response Rate (DRR)
Time Frame: 2 years
|
DRR is 50% or greater response to induction therapy based on RECIST criteria.
The objective is to intensify induction chemotherapy with the addition of an immune checkpoint inhibitor aimed at increasing the proportion of patients achieving a deep tumor response in order to subsequently allow risk-adapted definitive chemoradiotherapy in advanced stage HPV negative head and neck squamous cell cancer patients.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival rate (PFS)
Time Frame: 24 months
|
Progression free survival at 24 months after completing chemoradiation.
PFS will be defined as the time from registration to the date of the first documented disease progression, clinical progression, or death due to any cause, whichever occurs first.
|
24 months
|
Overall Survival rate (OS)
Time Frame: 24 months
|
Overall survival will be defined as the time between the date of registration and the date of death.
|
24 months
|
Locoregional control after completing chemoradiation
Time Frame: 24 months
|
assess disease control in all patients receiving induction chemoimmunotherapy and compare disease control between radiation arms.
|
24 months
|
Distant control after completing chemoradiation
Time Frame: 24 months
|
Distant control will be defined as the time from registration to the date of the first documented disease progression below the clavicles.
Comparison between the two radiation arms will be made.
|
24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute and late toxicity during treatment
Time Frame: 1 year
|
Assess long term and late toxicities in all patients receiving induction therapy and risk-adapted chemoradiotherapy after deep response to induction therapy.
Acute and late toxicities will be defined using the National Cancer Institute Common Terminology Criteria for Adverse Events.
Comparisons will be made using Fisher's exact test.
Acute and late toxicity during treatment and at 1 month, 3 months and 1 year post chemoradiation
|
1 year
|
Enteral tube dependency
Time Frame: 1 year
|
Enteral tube dependency will be defined as continued necessity of any nutrition through enteral tube to maintain weight.
The incidence of enteral tube dependency will be described within the safety population and among each radiation treatment.
Comparisons will be made using Fisher's exact test.
|
1 year
|
Performance Standard Scale for Head and Neck (PSS_HN) Quality of life assessments
Time Frame: 2 years
|
Evaluate quality of life in response in patients who receive dose reduced chemoradiotherapy after a deep response to induction therapy.
Quality of life assessments will be measured in the safety population.
Results will be tabulated and compared using the Fisher's exact test.
Overall and domain subset scores of the Performance Standard Scale for Head and Neck (PSS_HN) and Functional Assessment of Cancer Therapy scale Head and Neck quality of life assessments
|
2 years
|
Functional Assessment of Cancer Therapy scale Head and Neck Quality of life assessments
Time Frame: 2 years
|
Evaluate quality of life in response in patients who receive dose reduced chemoradiotherapy after a deep response to induction therapy.
Quality of life assessments will be measured in the safety population.
Results will be tabulated and compared using the Fisher's exact test.
Overall and domain subset scores of the Performance Standard Scale for Head and Neck (PSS_HN) and Functional Assessment of Cancer Therapy scale Head and Neck quality of life assessments
|
2 years
|
Immunohistological biomarkers
Time Frame: 2 years
|
Interrogate and understand the immune micro-environment at baseline 2-3 weeks into induction therapy with extensive immunohistological and serum biomarkers.
Use biomarker data and efficacy data.
These exploratory predictive biomarker analyses will be completed with biomarkers measured in the blood and in tumor samples obtained prior to and near completion of induction therapy.
The main tumor biomarkers measured will be PD-L1, tumor mutation burden, and T-cell activated gene signatures.
The relationship between measures will be investigated using logistic regression.
|
2 years
|
Serum biomarkers
Time Frame: 2 years
|
Interrogate and understand the immune micro-environment at baseline 2-3 weeks into induction therapy with extensive immunohistological and serum biomarkers.
Use biomarker data and efficacy data.
These exploratory predictive biomarker analyses will be completed with biomarkers measured in the blood and in tumor samples obtained prior to and near completion of induction therapy.
The main tumor biomarkers measured will be PD-L1, tumor mutation burden, and T-cell activated gene signatures.
The relationship between measures will be investigated using logistic regression.
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Everett Vokes, MD, University of Chicago
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Carcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Papilloma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Adjuvants, Immunologic
- Immune Checkpoint Inhibitors
- Antisickling Agents
- Carboplatin
- Paclitaxel
- Fluorouracil
- Nivolumab
- Lenograstim
- Hydroxyurea
Other Study ID Numbers
- IRB19-0162
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Carcinoma of the Head and Neck
-
National Cancer Institute (NCI)Not yet recruitingStage II Squamous Cell Carcinoma of the Head and Neck | Stage III Squamous Cell Carcinoma of the Head and Neck | Stage IV Squamous Cell Carcinoma of the Head and NeckUnited States
-
Washington University School of MedicineCelgene CorporationActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and NeckUnited States
-
Bristol-Myers SquibbActive, not recruitingSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage...United States
-
Arnaud Bewley, MDNational Cancer Institute (NCI); Genentech, Inc.TerminatedStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Glenn J. HannaSecura Bio, Inc.Active, not recruitingMetastatic Head and Neck Cancer | Advanced Head and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Advanced Head and Neck CancerUnited States
-
Hi-Q Marine Biotech International, Ltd.RecruitingSquamous Cell Carcinomas of the Head and NeckTaiwan
-
University of Southern CaliforniaSanofiTerminatedCarcinoma of the Head and NeckUnited States
Clinical Trials on Carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedBrain and Central Nervous System TumorsUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
AkesoRecruitingAdvanced Squamous Non Small Cell Lung CancerChina
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Eli Lilly and CompanyCompletedLung NeoplasmsUnited States